CEJ Fund

CEJ Fund, formally known as the Cancer Epigenetics Japan Fund, is a specialized venture capital vehicle focused on the advancement of cancer epigenetics research and commercialization. Established through a collaboration between Epigeneron and Mizuho Capital, the fund targets early-stage biotechnology companies and academic spin-offs that leverage epigenetic mechanisms for oncology drug discovery and diagnostics. By providing both capital and strategic industry expertise, the fund aims to bridge the gap between fundamental epigenetic research and clinical application. Its investment portfolio primarily includes Japanese startups working on novel therapeutic modalities and biomarker platforms within the oncology space.